GenesisCare - logo
Enquire now
Refer a patient

Your state: AU |

down arrow down arrow

Lung Cancer

Lung Cancer
2024-12-17T03:14:24.935Z

AMG 20230153

AMG 20230153
Lung cancer

A Phase 2 study evaluating efficacy, safety, tolerability and PK of AMG 193 in subjects with metastatic or locally advanced MTAP-deleted NSCLC who have previously received at least one line of treatment.

A Phase 2 study evaluating efficacy, safety, tolerability and PK of AMG 193 in subjects with metastatic or locally advanced MTAP-deleted NSCLC who have previously received at least one line of treatment.

Trial overview

Clinical Area

Medical oncology

Disease / Condition

Lung cancer

Study Phase

ll

Trial Identifiers

NCT06593522 

 

https://clinicaltrials.gov/study/NCT06593522

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

Prof. Nick Pavlakis
Nick
Pavlakis
View Profile
Profile Image - Prof. Nick Pavlakis

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

You are leaving our website

You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.